Cargando…
Clinical utilities of aromatase inhibitors in breast cancer
Aromatase is an enzyme that converts testosterones to estrogens. Inhibition of this enzyme has been shown to have several clinical utilities in breast cancer. Currently, there are three aromatase inhibitors (AIs) in clinical use, namely anastrozole, letrozole, and exemestane. AIs have been used in v...
Autor principal: | Chumsri, Saranya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427607/ https://www.ncbi.nlm.nih.gov/pubmed/26005359 http://dx.doi.org/10.2147/IJWH.S69907 |
Ejemplares similares
-
Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer
por: Kazi, Armina A, et al.
Publicado: (2014) -
Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013) -
Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010) -
The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
por: Lønning, P. E.
Publicado: (2011) -
Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)